Myopia remained a top concern for attendees.
Refractive procedures jumped 20 percent over Q4-2016.
Companies posted revenues totaling $7.9 billion.
Other companies raised $115 million, bringing the total for the past month to $150 million.
The segment is expected to top $6.1 billion by 2023.
The meeting featured presentations from several China- and Hong Kong-based ophthalmic start-ups, along with US, Israeli, and European firms.
The chain has 220 hospitals in mainland China, plus 88 in other countries, including the US.
A health survey conducted in 2014 revealed that 17.6 percent of the city’s 24 million residents have diabetes.
Under the reorganization plan, local governments would oversee post-approval marketing.
No Tesla will be given away this year, ending a promotional event that started in 2015.
The company’s platform is based on lipid-assembled drug delivery.
This is the first indication for Eylea in China.
The glaucoma treatment gained US FDA approval in December 2017.
The company's US approved procedure for progressive keratoconus is an epi-off procedure.
Allergan has been paring costs to prepare for the launch of a generic version of Restasis in 2018.
The company said the recall impacted 2017 revenues.
Developers say the eye drops are designed to work with a laser source to apply a pattern to the superficial layer of the corneal epithelium to change the refractive index.
You are not currently logged in.
©2018 Market Scope
Lost your Password